Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Regen BioPharma (RGBP) Profit After Tax (2016 - 2025)

Historic Profit After Tax for Regen BioPharma (RGBP) over the last 13 years, with Q3 2025 value amounting to -$572469.0.

  • Regen BioPharma's Profit After Tax fell 11143.98% to -$572469.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.3 million, marking a year-over-year decrease of 4597.7%. This contributed to the annual value of -$1.3 million for FY2025, which is 9072.09% down from last year.
  • As of Q3 2025, Regen BioPharma's Profit After Tax stood at -$572469.0, which was down 11143.98% from -$167292.0 recorded in Q2 2025.
  • Over the past 5 years, Regen BioPharma's Profit After Tax peaked at $67.0 million during Q2 2022, and registered a low of -$67.1 million during Q1 2022.
  • Moreover, its 5-year median value for Profit After Tax was -$130120.0 (2024), whereas its average is -$367323.2.
  • Examining YoY changes over the last 5 years, Regen BioPharma's Profit After Tax showed a top increase of 99407.33% in 2022 and a maximum decrease of 1527054.91% in 2022.
  • Quarter analysis of 5 years shows Regen BioPharma's Profit After Tax stood at $2.6 million in 2021, then tumbled by 38.16% to $1.6 million in 2022, then plummeted by 121.38% to -$349760.0 in 2023, then tumbled by 47.35% to -$515384.0 in 2024, then decreased by 11.08% to -$572469.0 in 2025.
  • Its last three reported values are -$572469.0 in Q3 2025, -$167292.0 for Q2 2025, and -$19354.0 during Q1 2025.